Literature DB >> 27664384

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers.

Piero Ruscitti1, Paola Cipriani1, Francesco Ciccia2, Francesco Masedu3, Vasiliki Liakouli1, Francesco Carubbi1, Onorina Berardicurti1, Giuliana Guggino2, Paola Di Benedetto1, Salvatore Di Bartolomeo1, Marco Valenti3, Giovanni Triolo2, Roberto Giacomelli4.   

Abstract

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significantly associated with mortality. In conclusion, adult MAS is associated with high mortality rate. Some clinical features at diagnosis may be predictive of MAS-associated death.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome

Mesh:

Substances:

Year:  2016        PMID: 27664384     DOI: 10.1016/j.autrev.2016.09.016

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  23 in total

1.  Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.

Authors:  Piero Ruscitti; Carmela Rago; Luciana Breda; Paola Cipriani; Vasiliki Liakouli; Onorina Berardicurti; Francesco Carubbi; Caterina Di Battista; Alberto Verrotti; Roberto Giacomelli
Journal:  Clin Rheumatol       Date:  2017-09-15       Impact factor: 2.980

2.  Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?

Authors:  Yoshifumi Tada; Satomi Inokuchi; Akihito Maruyama; Rie Suematsu; Mariko Sakai; Yuri Sadanaga; Nobuyuki Ono; Yojiro Arinobu; Syuichi Koarada
Journal:  Rheumatol Int       Date:  2018-07-26       Impact factor: 2.631

3.  Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.

Authors:  Piero Ruscitti; Paola Cipriani; Vasiliki Liakouli; Daniela Iacono; Ilenia Pantano; Francesco Caso; Federico Perosa; Fabiola Atzeni; Francesco Paolo Cantatore; Raffaele Scarpa; Francesco Ciccia; Roberto Giacomelli
Journal:  Rheumatol Int       Date:  2019-07-01       Impact factor: 2.631

4.  Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients.

Authors:  Ammouri Wafa; Harmouche Hicham; Radi Naoufal; Khibri Hajar; Razine Rachid; Benkirane Souad; Maamar Mouna; Mezalek Tazi Zoubida; Adnaoui Mohamed
Journal:  Clin Rheumatol       Date:  2022-02-18       Impact factor: 2.980

5.  Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study.

Authors:  Piero Ruscitti; Ilenia Di Cola; Onorina Berardicurti; Alessandro Conforti; Daniela Iacono; Ilenia Pantano; Gelsomina Rozza; Silvia Rossi; Ludovico De Stefano; Silvia Balduzzi; Antonio Vitale; Francesco Caso; Luisa Costa; Marcella Prete; Luca Navarini; Fabiola Atzeni; Giuliana Guggino; Federico Perosa; Luca Cantarini; Bruno Frediani; Carlomaurizio Montecucco; Francesco Ciccia; Roberto Giacomelli; Paola Cipriani
Journal:  Clin Rheumatol       Date:  2021-10-11       Impact factor: 3.650

6.  H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.

Authors:  P Ruscitti; P Cipriani; P Di Benedetto; V Liakouli; O Berardicurti; F Carubbi; F Ciccia; G Guggino; G Triolo; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

7.  Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers.

Authors:  Piero Ruscitti; Paola Cipriani; Francesco Masedu; Daniela Iacono; Francesco Ciccia; Vasiliki Liakouli; Giuliana Guggino; Francesco Carubbi; Onorina Berardicurti; Paola Di Benedetto; Marco Valenti; Giovanni Triolo; Gabriele Valentini; Roberto Giacomelli
Journal:  BMC Med       Date:  2016-12-01       Impact factor: 8.775

8.  The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome.

Authors:  Sung Soo Ahn; Sang Hyun Hwang; Seung Min Jung; Sang-Won Lee; Yong-Beom Park; Mijin Yun; Jason Jungsik Song
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

9.  The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.

Authors:  Judith Leyens; Tim Th A Bender; Martin Mücke; Christiane Stieber; Dmitrij Kravchenko; Christian Dernbach; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2021-07-22       Impact factor: 4.123

10.  The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile.

Authors:  Piero Ruscitti; Antonio Barile; Onorina Berardicurti; Roberto Giacomelli; Paola Cipriani; Sonia Iafrate; Paola Di Benedetto; Antonio Vitale; Francesco Caso; Luisa Costa; Federico Bruno; Francesco Ursini; Luca Navarini; Federica Sensini; Raffaele Scarpa; Bruno Frediani; Luca Cantarini; Carlo Masciocchi
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.